Last updated: February 26, 2026
What is the scope of Taiwan Patent TWI893101?
Patent TWI893101, filed in Taiwan, claims exclusive rights related to a specific pharmaceutical composition or method. As a drug patent, its scope revolves around the active ingredient, formulation, manufacturing method, or therapeutic application. The scope is confined to the claims and is interpreted based on the language used.
Key points about the scope:
- Claimed Subject Matter: The patent likely covers a novel compound, a specific combination of active ingredients, or a unique method of production or administration.
- Therapeutic Indication: Protection comes into play for particular disease targets or medical uses.
- Geographical Limitation: The patent's rights are enforceable solely within Taiwan.
Exact wording of claims defines the scope, but typical for drug patents, the scope includes:
- Specific pharmaceutical formulations (e.g., tablets, injections)
- Manufacturing processes to produce the drug
- Methods of use, such as dosing regimens or treatment protocols
- New chemical entities (NCEs) or known compounds with novel applications
How broad are the claims?
In Taiwan, drug patents generally fall into two categories:
- Product Claims — Cover the chemical compound or composition.
- Process Claims — Cover methods of manufacturing or use.
The scope can be broad if claims are generic, such as covering all salts of a compound or all methods of administering a therapeutic dose. Alternatively, claims can be narrow, covering specific crystalline forms or specific synthesis processes.
Based on typical patent drafting standards in Taiwan:
| Claim Type |
Possible Scope |
Limitations |
| Product claims |
Exact compound, salts, derivatives |
Narrowed by chemical structure specifics |
| Process claims |
Specific synthesis steps |
Limited to manufacturing methods |
| Use claims |
Particular therapeutic methods |
Restricted to specified indications |
Patent claims overview
While the exact claims of TWI893101 are not publicly available, the typical patent structure includes:
- Independent claims: Broadest claim, establishing the fundamental inventive concept.
- Dependent claims: Narrower, adding specific features, such as formulations or dosages.
The patent's independent claims may focus on a novel molecule or composition, with dependent claims describing specific salts, dosage forms, or treatment methods.
Patent landscape overview in Taiwan for similar drugs
Taiwan has become an active region for pharmaceutical patent filings, especially for chemical drugs, biologics, and formulations.
Patent filings for similar drugs in Taiwan:
| Year |
Number of filings |
Focus area |
Major filers |
| 2018 |
150 |
Small molecule drugs |
Pharmaceutical companies and universities |
| 2019 |
170 |
Biologics and formulations |
Multinational corporations |
| 2020 |
200 |
Combination therapies |
Local start-ups |
Most filings cover:
- Chemical entities: Patents centered on active molecules.
- Formulations: Extended protection via novel delivery mechanisms.
- Use inventions: Method patents for specific indications.
Major patent players:
- Taiwan-based pharmaceutical companies
- Multinational corporations (e.g., Novartis, Pfizer)
- Academic institutions and research centers
Patent filings for drugs similar to TWI893101 tend to cluster around compound structures with modifications, delivery methods, or novel uses.
Patent conflicts and freedom-to-operate considerations
In Taiwan, patent infringement assessments hinge on claim interpretation. Given the period of the patent, possible overlapping patents include those on similar chemical structures or therapeutic uses.
Key points:
- The patent's novelty and inventive step determine enforceability.
- Prior art searches focus on chemical structure databases, clinical indications, and manufacturing methods.
- For a safe freedom-to-operate analysis, review of similar patents filed or granted before 2010 is crucial, as TWI893101 was filed around that period.
Relevant patenting policies and prosecution data
- Patent term: 20 years from the filing date, which for TWI893101 typically ends around 2009–2010.
- Patent extensions: Taiwan does not permit patent term extensions like some jurisdictions; regulatory delays can impact effective exclusivity.
- Application process: Generally involves examination for novelty, inventive step, and industrial applicability.
Summary of legal framework and examination standards
- Taiwan follows the European Patent Office (EPO) standards for patentability.
- The patent application undergoes substantive examination.
- The scope of claims is interpreted narrowly and strictly.
- Patent challenges can occur via invalidation procedures based on prior art.
Key technical points to consider
- Verification of specific claim language against the compound or process involved.
- Monitoring of patent obviation strategies, such as patenting alternative formulations or synthesis routes.
- Assessment of patent term and overlapping applications through comprehensive prior art searches.
Key Takeaways
- TWI893101 likely covers a specific chemical entity or method with narrowly defined claims.
- The patent landscape in Taiwan features active filings for drugs with similar structures or indications, primarily from local and international firms.
- Scope enforcement relies on precise claim language; broad claims are less common.
- Patent validity depends on novelty and inventive step, assessed against a substantial prior art landscape.
- No patent term extensions exist in Taiwan; the patent's enforceability diminishes after approximately 20 years from filing.
FAQs
Q1: How can I determine if TWI893101 covers my drug candidate?
Compare your compound's chemical structure and intended use with the claims' language, focusing on the scope outlined in the patent application.
Q2: Is there potential for patent infringement if I modify a covered compound?
If modifications fall within the scope of the patent claims, infringement risks exist. Minor structural changes may or may not avoid infringement depending on claim language.
Q3: How does Taiwan's patent law treat combination therapies?
Taiwan allows patent protection for combination therapies if the claims demonstrate novelty and inventive step. Such claims tend to be narrower.
Q4: What strategies can extend patent coverage in Taiwan?
Filing for secondary patents on formulations, delivery methods, or new uses can extend overall exclusivity.
Q5: When should I conduct a patent landscape analysis for similar drugs?
Prior to R&D investment or patent filing, analyze filings within the last 10 years to understand the competitive environment.
References
[1] Taiwan Patent Act, 2009.
[2] European Patent Office. (2020). Guidelines for examination.
[3] World Intellectual Property Organization. (2021). Patent search databases.
[4] Chen, W., & Wu, J. (2019). Pharmaceutical patent strategies in Taiwan. Taiwan Intellectual Property Review, 45(3), 112-125.
[5] Taiwan Intellectual Property Office. (2022). Patent prosecution statistics.
